Clinical trials: Pulmonary Embolus/Emboli
Deep Vein Thrombosis, Pulmonary Embolism
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of…
- Trial name
- DANNOAC-VTE (NCT03129555)
- Testing
- Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet
- Where
- 26 sites in Denmark
- Volunteers
- 5,000 people
- Sponsor
- Herlev and Gentofte Hospital
Venous Thromboembolism, Deep-Vein Thrombosis
Implementing a Tool to Identify Risk for Venous Thromboembolism in Cancer Patients
Cancer increases the risk of deep vein blood clots and clots traveling to the lungs (emboli) which cause morbidity (leg swelling, pain, and shortness of breath), sudden death, delays cancer treatment, and decreases cancer…
- Conditions
- Venous Thromboembolism, Deep-Vein Thrombosis, Pulmonary Embolism, Cancer
- Trial name
- NCT01602432
- Where
- Canada
- Sponsor
- Ottawa Hospital Research Institute
Pulmonary Embolism, Deep Vein Thrombosis
Predicting the Safety and Effectiveness of Inferior Vena Cava Filters
PRESERVE is a multi-center, prospective, open-label, non-randomized investigation of commercially available IVC filters from 6 manufacturers placed in subjects for the prevention of pulmonary embolism (PE).
- Trial name
- PRESERVE (NCT02381509)
- Testing
- IVC Filter
- Where
- 53 sites in United States
- Volunteers
- 1,428 people
- Sponsor
- Carelon Research
Venous Thrombosis, Pulmonary Embolism
Extended Out-of-hospital Low-molecular-weight Heparin Prophylaxis Against DVT and PE in Patients Undergoing Major Lung Resection
Postoperative venous thromboembolism (VTE) is a significant health-care problem, resulting in significant morbidity, mortality and resource utilization. The true incidence is unknown, and may range from 1% to 15%.
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Lung Neoplasms
- Trial name
- NCT02258958
- Where
- 2 sites in Canada
- Volunteers
- 150 people
- Sponsor
- McMaster University
Deep Venous Thrombosis, Pulmonary Embolus
Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose
Venous thromboembolism (VTE) encompasses deep venous thrombosis and pulmonary embolus, and is the proximate cause of death in over 100,000 hospitalized patients per year.
- Conditions
- Deep Venous Thrombosis, Pulmonary Embolus, Venous Thromboembolism
- Trial name
- NCT02704052
- Testing
- Real time enoxaparin dose adjustment, Standard enoxaparin dose
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- University of Utah
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT)
Decision Aid for Anticoagulation Duration After Unprovoked Venous Thromboembolism
Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a common condition that is typically treated with blood thinners (anticoagulants).
- Conditions
- Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism
- Trial name
- DECIDE-VTE (NCT07659106)
- Testing
- DECIDE-VTE Patient Decision Aid
- Where
- 5 sites in Canada
- Volunteers
- 850 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Deep Vein Thrombosis
Understanding Risk Factors Involved in Developing a Second Blood Clot.
The purpose of this study is to develop a way to predict which patients diagnosed with idiopathic blood clots can safely stop warfarin therapy after six months.
- Trial name
- NCT00261014
- Where
- 7 sites in Canada, France
- Volunteers
- 800 people
- Sponsor
- Ottawa Hospital Research Institute
Hypertension, Pulmonary
Simvatstatin Used to Treat Pulmonary Hypertension
we try to use simvastatin in the treatment of advanced pulmoary hypertension secondary to congenital heart disease or chronic pulmonary embolism before and after the operation.
- Trial name
- NCT00538044
- Testing
- simvastatin
- Where
- China
- Sponsor
- Capital Medical University
Pulmonary Embolism
Strategies to Reduce Contrast Medium in Spectral CT Pulmonary Angiography
The purpose of this study is to assess the effect of three different strategies to inject at reduced volume of contrast medium in Computed Tomography Pulmonary Angiography (CTPA).
- Trial name
- NCT05592444
- Testing
- Low iodine Spectral Detector CT Pulmonary Angiography
- Where
- Norway
- Volunteers
- 330 people
- Sponsor
- University Hospital, Akershus
COVID-19, Hemostasis
Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy
The understanding of haemostasis and inflammation cross-talk has gained considerable knowledge during the past decade in the field of arterial and venous thrombosis.
- Conditions
- COVID-19, Hemostasis, Coagulation
- Trial name
- THROMBCOVID2 (NCT04377490)
- Testing
- venous ultrasound, blood sample
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Venous Thrombosis, Pulmonary Embolism
Deep Venous Thrombosis After Hepatobiliopancreatic Surgery
To investigate the incidence of pre- and early postoperative deep venous thrombosis in patients undergoing hepatobiliopancreatic surgery, as well as potential corresponding risk factors with special attention to circulating tumor…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Hepatectomy, Pancreatectomy
- Trial name
- POPLITEA (NCT02649023)
- Where
- Germany
- Volunteers
- 76 people
- Sponsor
- Technische Universität Dresden
Cancer, Venous Thromboembolism
CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)
The aim of the study is to evaluate the efficacy and safety of Bemiparin, a second-generation LMWH, in the prophylaxis of VTE (using a postoperative regimen, i.e.
- Trial name
- NCT00219973
- Testing
- Bemiparin
- Where
- 4 sites in Portugal, Romania and 2 more
- Volunteers
- 526 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Covid19
COVID-19 And Geko Evaluation: The CAGE Study
The primary objectives of this pilot study protocol are to assess safety and feasibility of using the geko™ device in COVID-19. Regarding safety to patients, we will measure the rate of adverse events, primarily local site…
- Trial name
- CAGE (NCT04651374)
- Testing
- geko T3
- Where
- Canada
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Thrombosis, Venous
Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer
This study will evaluate the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer or non-small-cell lung carcinoma (NSCLC).
- Trial name
- NCT00312013
- Testing
- Nadroparin
- Where
- 95 sites in Belgium, Canada and 9 more
- Volunteers
- 503 people
- Sponsor
- GlaxoSmithKline
Pulmonary Embolism
SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism
Patients who have a pulmonary embolism (blood clot in the lung) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood-thinning) drug, SR34006…
- Trial name
- NCT00062803
- Testing
- SR34006, (LMW)heparin, Warfarin VKA
- Where
- 93 sites in United States, Argentina and 18 more
- Sponsor
- Sanofi
Recurrent Venous Thrombosis
Risk of Recurrent Venous Thromboembolism After Provoked Venous Thromboembolism
Venous thromboembolism (VTE) is a common disease with an incidence of 1-2/1000 persons per year. VTE is a chronic disease with a considerable risk of recurrence. Patients with unprovoked VTE, i.e.
- Trial name
- AURECpro (NCT04124159)
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Medical University of Vienna
Acute Disease, Sepsis
Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Research in acute care faces many challenges, including enrollment challenges, legal limitations in data sharing, limited funding, and lack of singular ownership of the domain of acute care.
- Conditions
- Acute Disease, Sepsis, Pneumonia, Frailty
- Trial name
- Acutelines (NCT04615065)
- Where
- Netherlands
- Volunteers
- 35,000 people
- Sponsor
- University Medical Center Groningen
Pulmonary Embolism
Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 3 ("RETRIEVE 3")
The purpose of this study is to determine if the Crux Vena Cava Filter System is safe and effective in preventing pulmonary embolism.
- Trial name
- RETRIEVE 3 (NCT01120522)
- Testing
- Inferior Vena Cava Filter
- Where
- 2 sites in Belgium
- Volunteers
- 17 people
- Sponsor
- Crux Biomedical
Venous Thromboembolism, Active Cancer
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to compare the clinical efficacy and safety of edoxaban-based treatment versus apixaban-based treatment in patients with cancer-associated venous…
- Trial name
- NEXT-CAT (NCT07852637)
- Testing
- edoxaban, Apixaban
- Where
- 12 sites in South Korea
- Volunteers
- 2,300 people
- Sponsor
- Samsung Medical Center
Pulmonary Embolism Acute
RDW and RV-PA Coupling in Acute PE
Prior work linking RDW to echocardiographic findings in PE has largely focused on isolated parameters such as TAPSE or PASP and has rarely incorporated modern measures of RV-PA coupling.
- Trial name
- NCT07616557
- Testing
- Echo-cardiography
- Volunteers
- 190 people
- Sponsor
- Assiut University